CONTEXT: While prostate-specific antigen testing and biopsy are the most conclusive ways for detecting prostate cancer, no clear-cut imaging technique exists for initial diagnosis and staging.
CONTEXT: While prostate-specific antigen testing and biopsy are the most conclusive ways for detecting prostate cancer, no clear-cut imaging technique exists for initial diagnosis and staging. A preliminary study led by Dr. David Schuster, director of nuclear medicine and molecular imaging at Emory University, analyzed the PET agent anti-fluorine-18 FACBC for these roles. The amino acid-based radiotracer (a synthetic L-leucine analog) is designed to have properties of optimal nonspecific binding and metabolism. Compared with FDG, which does not accumulate in prostate tumors, anti-F-18 FACBC shows little renal excretion.
RESULTS: Following an injection of anti-F-18 FACBC, nine patients with newly diagnosed prostate cancer were scanned with PET/CT. Subjects underwent 65 minutes of dynamic imaging of the pelvis followed by static whole-body imaging. Maximum standard uptake value, recorded in the right and left lobes of the prostate and within lymph nodes, peaked within six minutes after infusion and remained significantly higher for at least 50 minutes in primary and metastatic prostate carcinoma compared with benign regions in 14 of 16 lobes. Malignant sextants and nodes had significantly higher SUVmax than did benign regions, though the numbers in this pilot study were small.
Visual analysis often successfully identified the presence or absence of neoplasia. Four false positives associated with inflammation and four false negatives stemming from microscopic disease arose from interpretation of delayed images. Uptake was elevated for recurrent disease in the prostate bed, and associated nodal and skeletal metastases often appeared when indium-111 ProstaScint uptake was not evident.
IMAGE: Intense FACBC uptake, indicative of recurrent cancer, appears in small right common iliac nodes (left). Corresponding ProstaScint SPECT image of the same patient was negative for iliac lymph node involvement.
IMPLICATIONS: Pilot data suggest anti-F-18 FACBC will be an effective agent for imaging early prostate cancer compared with FDG-PET/CT or In-111 ProstaScint. Lymph imaging indicates it could help differentiate between prostatic and extraprostatic reccurrence, Schuster said. Following on these positive yet limited results, subsequent trials will examine more patients to develop a strategy for clinical imaging.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
What is the Best Use of AI in CT Lung Cancer Screening?
April 18th 2025In comparison to radiologist assessment, the use of AI to pre-screen patients with low-dose CT lung cancer screening provided a 12 percent reduction in mean interpretation time with a slight increase in specificity and a slight decrease in the recall rate, according to new research.
Meta-Analysis Shows Merits of AI with CTA Detection of Coronary Artery Stenosis and Calcified Plaque
April 16th 2025Artificial intelligence demonstrated higher AUC, sensitivity, and specificity than radiologists for detecting coronary artery stenosis > 50 percent on computed tomography angiography (CTA), according to a new 17-study meta-analysis.